Top Story

Enrollment open for phase 2 trial of Melphalan/HDS for HCC

May 25, 2015

Delcath Systems, Inc. announced the intrahepatic cholangiocarcinoma study cohort of its global phase 2 trial of Melphalan/HDS therapy for the treatment of unresectable hepatocellular carcinoma is now enrolling patients, according to a press release.

The trial will investigate the safety and efficacy of melphalan/HDS therapy (melphalan hydrochloride for injection with the hepatic delivery system, Delcath) in patients with unresectable intrahepatic cholangiocarcinoma (ICC) confined to the liver. The melphalan/HDS is a system designed to supply high-dose chemotherapy to the liver while controlling systemic exposure, according to the Delcath website.

Cover StoryPublication Exclusive

Despite promise, ‘maximum potential’ of precision medicine yet to be reached

HemOnc Today, May 25, 2015
Precision medicine has garnered tremendous public attention since President Barack Obama established it as a national priority during his State of the Union address.The…
David A. Williams, MD Association News

ASH announces training program participants

May 24, 2015
ASH and the European Hematology Association released the names of 20 early-career hematologists who are participating in the 2015 Translational Research in Hematology…
Martin McMahon, PhD Institution Notes

Cancer institute appoints senior director

May 23, 2015
Martin McMahon, PhD, has been appointed professor in the department of dermatology and senior director of pre-clinical translation at Huntsman Cancer Institute at the…
In the Journals

Statins may lower mortality risk in patients with lung cancer

May 22, 2015
Statin use in the year before and after diagnosis was linked to decreased mortality risk in patients with lung cancer, according to results of a population-based cohort…
More News Headlines »
CME
Hematology Oncology Case Consults

The Patient with Melanoma

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with melanoma.
More »
Meeting News Coverage Video
VIDEO: Updates in prostate cancer treatment options

VIDEO: Updates in prostate cancer treatment options

May 5, 2015
Robert S. DiPaola, MD, director of Rutgers Cancer Institute of New Jersey, discusses various forms of prostate cancer…
More »
CME CNE
High Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
morganatic-roan